Mathias Schmidt, Ph.D.›
Chief Executive Officer
Dr. Schmidt joined ArmaGen as the chief executive officer, as well as member of ArmaGen’s board of directors, in October 2016. Dr. Schmidt has more than 17 years of global biopharmaceutical industry experience in executive management focused on the research and development of biotherapeutics and pharmaceuticals. Prior to ArmaGen, he held various positions with Takeda Pharmaceuticals and its subsidiaries since 2001, including oncology drug discovery, early alliance management and overseeing biologics. He joined Takeda California in 2012 as Vice President of Biological Sciences where he built a highly functional Biotherapeutics unit serving all therapeutic indications and all research sites within the global Takeda organization. In 2011, he was awarded the venia legendi in pharmacology from the University of Konstanz. He and his team developed a HER-2 specific immunotoxin that subsequently entered the clinic when he studied at the University of Freiburg. After working for several years at various cancer hospitals in Germany and the U.S., he joined the pharmaceutical industry in 1999, where he developed a great passion for drug discovery and development, especially for protein therapeutics.
He holds an M.S. degree in Biotechnology from the University of Stuttgart (Germany) and a Ph.D. in Tumor Biology (summa cum laude) from the University of Freiburg. He studied cellular biology and pharmacology at the University of Constance.
William M. Pardridge, M.D.›
Founder and Chief Scientific Officer
Dr. Pardridge formed ArmaGen in 2003 and supported the company the first 10 years with $20 million in non-dilutive funding. Dr. Pardridge, who is a Distinguished Professor Emeritus, UCLA, is a recognized leader in blood-brain barrier (BBB) research. He has focused on the area since 1970, and is credited with inventing the antibody directed receptor-mediated transcytosis technology, the liposome technology for non-viral, non-invasive gene therapy of the brain, and the field of BBB genomics. He is the author of over 500 publications, more than 450 of which focus on the BBB. Dr. Pardridge is board certified in Internal Medicine, and Endocrinology and Metabolism.
Ruben Boado, Ph.D.›
Co-founder and Vice President of Research and Development
Dr. Boado co-founded ArmaGen in 2004, following more than 25 years of academic experience in fields of molecular and cell biology of the BBB, and drug delivery to the brain. His leadership and expertise have been instrumental in the development of ArmaGen’s extensive product pipeline, including potential biotherapeutic treatments for mucopolysaccharidosis, stroke, Alzheimer’s disease and Parkinson’s disease. Dr. Boado was the principal investigator in a number of Small Business Innovation Research (SBIR) programs granted by the National Institutes of Health to ArmaGen. Dr. Boado is also a co-inventor of the intellectual property that supports ArmaGen’s pipeline. He was previously professor of Medicine at UCLA, and has published over 195 scientific peer-reviewed publications and book chapters related to the BBB. Dr. Boado received his Ph.D. in Biochemistry at the University of Buenos Aires.
Joseph G. Phillips, Ph.D.›
Senior Vice President of Pharmaceutical Development
Dr. Joseph Phillips joined ArmaGen in May 2017. In his 27 years of leadership experience in the biopharmaceutical industry he has managed organizations engaged in drug substance and drug product manufacturing process development serving R&D and manufacturing operations.
He led advanced work in genomics, proteomics and metabolomics technologies to understand how cell culture media constituents, bioprocess raw materials and processing conditions impact product quality attributes and productivity to improve prediction of manufacturing results. He pursued the use of high resolution analytical techniques to measure human biological transformation and physiological clearance of drug product variants to assign critical product quality attributes.
Prior to joining ArmaGen, Joseph was a biotechnology consultant to biopharmaceutical executive leaders for bioprocess & product development CMC, manufacturability, QbD, cGMP and technical operations.
Before his consultancy, Joseph held several Executive Director positions at Amgen delivering successful global CMC regulatory submissions for Neulasta, Aranesp, Sensipar/Mimpara, Enbrel, Vectibix, Prolia, XGEVA and Repatha. Prior to Amgen, he served in several leadership roles at GlaxoSmithKline. He started his career in the biopharmaceutical industry at Upjohn (acquired by Pharmacia/Pfizer). Joseph received his Ph.D. in pharmaceutics and analytical chemistry from Brighton University (UK), his M.Sc. in organometallic chemistry from University of Sussex (UK) and his B.Sc. in applied chemistry from Brighton University (UK).
Douglas Hunt, FRAPS›
Vice President of Regulatory Affairs and Quality Assurance
Douglas Hunt has more than 20 years of biopharmaceutical experience, during which he has filed numerous Biologic License Applications (BLAs) and Investigational New Drug (IND) applications. Prior to joining ArmaGen in May 2015, he served as Vice President Global Regulatory Affairs of Baxter Bioscience, a leading manufacturer of recombinant and plasma-based proteins to treat immune deficiencies, hemophilia and other bleeding disorders. Before his tenure at Baxter, Douglas worked at Amgen in various roles of increasing responsibility in both regulatory affairs and manufacturing. Prior to that, he was Senior Director Global Regulatory Affairs at Quintiles. During his tenure at Baxter and Amgen, he led teams that supported global approvals of OBIZUR, RIXUBIS, HYQVIA, PreFLUCEL, NPLATE, ARANESP, ENBREL and NEULASTA. Prior to Quintiles, Mr. Hunt received his B.Sc. in biological sciences from Portsmouth University (UK).
Derek Kelaita, MBA›
Vice President of Business Development
Mr. Kelaita has more than 15 years of business/corporate development experience negotiating in-licensing, out-licensing transactions as well as strategic collaborations for public/private biopharmaceutical companies. He has been responsible for licensing/M&A transactions valued at over $1 billion in multiple therapeutic areas including: orphan drugs (ArmaGen), immunotherapy (AnaptysBio), metabolic/diabetes (Cebix), dental (Novalar), infectious disease (Nventa), oncology (Dendreon) and cardiovascular disease (Corvas). Mr. Kelaita brings to ArmaGen a history of successfully directing cross-functional teams of senior executives to achieve business development objectives and provides strategic and tactical advice in the areas of corporate/business development, investor relations, public relations, intellectual property, finance and market research.